Orexigen Therapeutics said the US District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against Actavis Laboratories FL for three patents for weight loss drug Contrave, with exclusivity through 2030.
“Orexigen’s intent was to vigorously defend our intellectual property and we are very pleased with the court’s decision upholding the validity of all of the patents involved in the case,” said Orexigen CEO Michael Narachi.
“The court’s positive decision allows Orexigen to continue to fulfill its mission to provide innovative medicine to treat patients who are overweight or struggling with obesity …
“As we progress on our path to profitability by 2019, we expect that exclusivity through 2030 will provide many valuable years of growing profitability for Contrave.”
Orexigen said it filed the lawsuit in response to an Abbreviated New Drug Application (ANDA) filed by Actavis, which sought to market and sell a generic version of the currently approved dose of Contrave tablets, prior to the expiration of US patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.